Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib versus imatinib as initial therapy for unresectable or metastatic gastrointestinal stromal tumors
2008-004758-34Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Nilotinib arm with Imatinib arm (2 arms). Primary endpoint: Progression-free survival. Started Nov 2008; status: completed.
02
Drugs
nilotinibimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2008-004758-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004758-34.